surfactant protein A3, pseudogeneGenealiases: COLEC6 · SFTPAP1 · SFTPP1
Q-omics provides the consensus-scored SFTPA3P profile across patient tissues and cancer cell-line models. SFTPA3P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SFTPA3P is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, SFTPA3P RNA expression shows 6,473 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, and STAD as cancer lineages where SFTPA3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SFTPA3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SFTPA3P survival associations across molecular data types. SFTPA3P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SFTPA3P RNA expression–survival associations across cancer types. High SFTPA3P expression shows unfavorable associations in LUSC, BLCA, SARC, UCS, SKCM and PCPG. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify LUSC as the clearest survival context for SFTPA3P RNA expression.
This table summarizes SFTPA3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SFTPA3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SFTPA3P shows lower tumor expression in LUSC, BRCA and LUAD. The LUSC box plot shows higher SFTPA3P RNA expression in normal versus tumor tissue (log2 FC = −0.236, t-test p < 0.001).
This table shows molecular features associated with SFTPA3P in patient tissues and cancer cell lines. In patient samples, SFTPA3P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
